JP2010502979A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502979A5
JP2010502979A5 JP2009527200A JP2009527200A JP2010502979A5 JP 2010502979 A5 JP2010502979 A5 JP 2010502979A5 JP 2009527200 A JP2009527200 A JP 2009527200A JP 2009527200 A JP2009527200 A JP 2009527200A JP 2010502979 A5 JP2010502979 A5 JP 2010502979A5
Authority
JP
Japan
Prior art keywords
individual
liver
liver disease
adma
suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009527200A
Other languages
English (en)
Japanese (ja)
Other versions
JP4949473B2 (ja
JP2010502979A (ja
Filing date
Publication date
Priority claimed from GBGB0617581.4A external-priority patent/GB0617581D0/en
Application filed filed Critical
Publication of JP2010502979A publication Critical patent/JP2010502979A/ja
Publication of JP2010502979A5 publication Critical patent/JP2010502979A5/ja
Application granted granted Critical
Publication of JP4949473B2 publication Critical patent/JP4949473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009527200A 2006-09-07 2007-09-07 肝機能を評価するためのバイオマーカー Active JP4949473B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0617581.4 2006-09-07
GBGB0617581.4A GB0617581D0 (en) 2006-09-07 2006-09-07 Biomarkers for assessing liver function
PCT/GB2007/003362 WO2008029145A1 (en) 2006-09-07 2007-09-07 Biqmarkers for assessing liver function

Publications (3)

Publication Number Publication Date
JP2010502979A JP2010502979A (ja) 2010-01-28
JP2010502979A5 true JP2010502979A5 (cg-RX-API-DMAC7.html) 2010-10-21
JP4949473B2 JP4949473B2 (ja) 2012-06-06

Family

ID=37232490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009527200A Active JP4949473B2 (ja) 2006-09-07 2007-09-07 肝機能を評価するためのバイオマーカー

Country Status (16)

Country Link
US (1) US8455220B2 (cg-RX-API-DMAC7.html)
EP (1) EP2059817B1 (cg-RX-API-DMAC7.html)
JP (1) JP4949473B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090083335A (cg-RX-API-DMAC7.html)
AT (1) ATE488772T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007293302A1 (cg-RX-API-DMAC7.html)
CA (1) CA2662597A1 (cg-RX-API-DMAC7.html)
DE (1) DE602007010644D1 (cg-RX-API-DMAC7.html)
EA (1) EA200970256A1 (cg-RX-API-DMAC7.html)
ES (1) ES2353835T3 (cg-RX-API-DMAC7.html)
GB (1) GB0617581D0 (cg-RX-API-DMAC7.html)
IL (1) IL197271A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009002378A (cg-RX-API-DMAC7.html)
NO (1) NO20090993L (cg-RX-API-DMAC7.html)
WO (1) WO2008029145A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200901432B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012262329B2 (en) 2011-05-31 2014-10-16 The Regents Of The University Of Colorado, A Body Corporate Method for assessment of hepatic function and portal blood flow
CA3191764A1 (en) * 2012-11-12 2014-05-15 The Regents Of The University Of Colorado, A Body Corporate Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
US10054600B2 (en) 2013-05-22 2018-08-21 The Regents Of The University Of California Biomarker composite test for hepatic vein pressure gradient and cirrhosis treatment
CA2965325A1 (en) * 2014-10-24 2016-04-28 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
CN105181692A (zh) * 2015-09-30 2015-12-23 山东博科生物产业有限公司 一种缺血修饰白蛋白比色法检测试剂盒
US10793909B2 (en) 2015-11-10 2020-10-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time of patients with decompensated alcoholic cirrhosis
US20220018852A1 (en) * 2018-11-20 2022-01-20 Inserm (Institute National De Ka Santé Et De La Recherche Médicale) Methods and kits for detecting liver dysfunction in a subject

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034605A1 (en) 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
AU2001275870A1 (en) 2000-07-06 2002-01-21 Fal Diagnostics Methods and kits for the detection of arginine compounds
US7063782B2 (en) * 2001-11-26 2006-06-20 Ischemia Technologies, Inc. Electrochemical detection of ischemia
WO2004012686A2 (en) * 2002-08-06 2004-02-12 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
WO2004046314A2 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for detecting asymmetric dimethylarginine in a biological sample
WO2005039598A1 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Method of treating alcoholic liver disease
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern

Similar Documents

Publication Publication Date Title
JP2010502979A5 (cg-RX-API-DMAC7.html)
Duseja et al. APACHE II score is superior to SOFA, CTP and MELD in predicting the short‐term mortality in patients with acute‐on‐chronic liver failure (ACLF)
Sarin et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014
Sanghera et al. Obesity genetics and cardiometabolic health: Potential for risk prediction
Kahli et al. Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass
RU2009139295A (ru) Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек
BR112012006678A2 (pt) método para criar um arranjo proteico, arranjo proteico e métodos para determinar a especificidade da ligação de um anticorpo ou preparação de anticorpos, para determinar biomarcadores de doenças, para diagnosticar uma doença, para monitorar as vias de transdução de sinais e para determinar interações entre pequenas moléculas e proteínas
JP2011510327A5 (cg-RX-API-DMAC7.html)
JP2011501176A5 (cg-RX-API-DMAC7.html)
Kelsey et al. ENU-induced mutation in the DNA-binding domain of KLF3 reveals important roles for KLF3 in cardiovascular development and function in mice
Aleem et al. Correlation of C-reactive protein levels with severity of chronic urticaria
Zhang et al. EPAS1 and VEGFA gene variants are related to the symptoms of acute mountain sickness in Chinese Han population: a cross-sectional study
Zhang et al. The early predictive role of complement C3 and C4 in patients with acute pancreatitis
Guzmán-Bárcenas et al. Clara cell protein expression in mechanically ventilated term and preterm infants with respiratory distress syndrome and at risk of bronchopulmonary dysplasia: a pilot study
WO2012019099A3 (en) Follistatin-like-protein-1 as a biomarker for inflammatory disorders
Paradis et al. Quantitative gene expression in Budd-Chiari syndrome: a molecular approach to the pathogenesis of the disease
WO2008039445A3 (en) Polymorphisms in the human xbp-1 gene are associated with inflammatory bowel disease
Vukobrat-Bijedic et al. Use of Serum Levels of Proinflammatory Cytokine IL–1α in Chronic Hepatitis B
Kumar et al. Genetic variation in CCDC93 is associated with elevated central systolic blood pressure, impaired arterial relaxation, and mitochondrial dysfunction
JP2009520696A5 (cg-RX-API-DMAC7.html)
Fujita et al. Calcium “stress” adds a third hit in driving heart failure with preserved ejection fraction
Pácal et al. HFE C282Y gene variant is a risk factor for the progression to decompensated liver disease in chronic viral hepatitis C subjects in the Czech population
Hunter Environmental Ozone Exposure, Gestational Health, and the Lung-Placental Axis
Miceli et al. Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin‐22, interleukin‐6 and interleukin‐1Ra concentrations according to portal hypertension and disease severity
Srivastava et al. Extracellular miRNAs as Predictors of CKD Progression: TH-OR12